title: Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
abstract: To evaluate the prognostic values of different protein expression in the progression of squamous cell carcinoma of the head and neck (SCCHN) patients, we conducted immunohistochemical (IHC) analysis in tissue samples of different patients enrolled on SWOG protocol S0420. S0420 was a phase II trial to evaluate the efficacy and safety of single-agent sorafenib in chemotherapy-naïve patients with metastatic or recurrent SCCHN. The primary end point was response probability, i.e., confirmed complete (CR) and partial response (PR). Sorafenib was administered orally at 400 mg twice daily on a continuous basis in 28-day cycles to eligible patients. Responses were evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria. IHC analysis was performed for various markers and data were analyzed statistically. IHC data were obtained from 19 patients enrolled on S0420. There was a high frequency of cases with expression of the angiogenesis markers SMA, HIF-1α, Raf-1, VEGF and VEGF-R. None of the markers were significantly associated with response. Negative HER-2 status was associated with longer progression-free survival (PFS), P=0.04. Negative NRP-1 status was associated with longer overall survival (OS), P=0.04. There were no other significant associations. An almost universal overexpression of angiogenesis markers in the samples analyzed supports the evaluation of angiogenesis inhibition as a potential target for therapy. High levels of NRP-1 and HER-2 in SCCHN samples appear to be associated with decreased survival and earlier progression of disease, respectively, in SCCHN patients and may represent targets for therapy.
authors.affiliation: Department of Hematology and Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.
authors.forename: Smita
authors.initials: S
authors.lastname: Mehta
authors.forename: James
authors.initials: J
authors.lastname: Moon
authors.forename: Mehmood
authors.initials: M
authors.lastname: Hashmi
authors.forename: Michael
authors.initials: M
authors.lastname: Leblanc
authors.forename: Chao Hui
authors.initials: CH
authors.lastname: Huang
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Rinehart
authors.forename: Gregory T
authors.initials: GT
authors.lastname: Wolf
authors.forename: Susan G
authors.initials: SG
authors.lastname: Urba
authors.forename: Sushanta K
authors.initials: SK
authors.lastname: Banerjee
authors.forename: Stephen
authors.initials: S
authors.lastname: Williamson
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D039942:Neuropilin-1 / Q000378:metabolism; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D039942:Neuropilin-1; D009536:Niacinamide; D010671:Phenylurea Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; D000077157:Sorafenib; C508053:ERBB2 protein, human
references.citation: Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H459-74
references.pmid: 16980341
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3766-73
references.pmid: 17704426
references.citation: PLoS Comput Biol. 2006 Dec 29;2(12):e180
references.pmid: 17196035
references.citation: J Clin Oncol. 1992 Aug;10(8):1245-51
references.pmid: 1634913
references.citation: Lancet Oncol. 2010 Jan;11(1):21-8
references.pmid: 19897418
references.citation: Blood. 2011 Jan 20;117(3):920-7
references.pmid: 21063027
references.citation: Invest New Drugs. 1996;14(4):403-7
references.pmid: 9157077
references.citation: Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Dec;15(6):1150-5
references.pmid: 18088455
references.citation: Br J Cancer. 1998 Jun;77(12):2120-8
references.pmid: 9649123
references.citation: J Clin Oncol. 2001 Feb 15;19(4):1088-95
references.pmid: 11181673
references.citation: Mol Cancer Ther. 2007 Jun;6(6):1785-92
references.pmid: 17575107
references.citation: Oncol Rep. 2003 Sep-Oct;10(5):1067-71
references.pmid: 12883660
references.citation: Exp Cell Res. 2006 Mar 10;312(5):594-607
references.pmid: 16376330
references.citation: Exp Cell Res. 2006 Mar 10;312(5):549-60
references.pmid: 16336962
references.citation: Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
references.pmid: 16633338
references.citation: Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2851-60
references.pmid: 15708957
references.citation: Invest New Drugs. 1998-1999;16(3):271-4
references.pmid: 10360608
references.citation: Int J Cancer. 2002 Oct 10;101(5):409-14
references.pmid: 12216067
references.citation: Head Neck. 2007 Jul;29(7):655-64
references.pmid: 17315173
references.citation: N Engl J Med. 2008 Sep 11;359(11):1116-27
references.pmid: 18784101
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4759-68
references.pmid: 17699853
references.citation: Head Neck. 2000 Sep;22(6):599-608
references.pmid: 10941162
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3330-5
references.pmid: 20498388
references.citation: Head Neck. 2003 Jun;25(6):464-74
references.pmid: 12784238
references.citation: Drugs. 2010 Oct 22;70(15):1987-2010
references.pmid: 20883055
references.citation: J Clin Oncol. 2005 May 20;23(15):3562-7
references.pmid: 15908667
references.citation: Trends Mol Med. 2011 Jul;17(7):347-62
references.pmid: 21481637
references.citation: Cancer. 2009 Mar 1;115(5):922-35
references.pmid: 19156911
references.citation: Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Jul;20(14):634-5
references.pmid: 17017185
references.citation: Leukemia. 2006 Nov;20(11):1950-4
references.pmid: 16990775
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Invest Ophthalmol Vis Sci. 2004 Feb;45(2):368-74
references.pmid: 14744874
references.citation: J Cell Biochem. 2002;85(2):357-68
references.pmid: 11948691
references.citation: Clin Cancer Res. 1999 Dec;5(12):4164-74
references.pmid: 10632356
references.citation: Am J Pathol. 2000 Jan;156(1):217-25
references.pmid: 10623670
references.citation: Invest New Drugs. 2001;19(4):311-5
references.pmid: 11561690
references.citation: Curr Med Chem. 2011;18(23):3563-75
references.pmid: 21756227
references.citation: Oral Oncol. 2009 Apr-May;45(4-5):409-15
references.pmid: 18715812
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3312-8
references.pmid: 19451442
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544